The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

The FDA has approved GSK’s Exdensur (depemokimab-ulaa) as an add-on maintenance therapy for adolescents and adults with severe asthma characterized by an eosinophilic phenotype. 1 ...

Osteoarthritis (OA) is a chronic degenerative joint disease marked by progressive cartilage breakdown, inflammation, and impaired tissue remodeling. A major driver of this degeneration is aberrant ...

As a chronic immune system disease, eosinophilic esophagitis (EoE) is characterized by symptoms like trouble swallowing, chest pain, and regurgitation of undigested food. But the condition can come ...

TUESDAY, Oct. 28, 2025 (HealthDay News) -- For patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) admitted to the intensive care unit (ICU), lower eosinophil counts are ...

Aqilion, a Swedish biopharma company developing therapies for diseases driven by chronic inflammation and dysregulated immune responses, has reported positive results from a pharmacokinetic study ...

Celldex Therapeutics, Inc.'s barzolvolimab failed to improve symptoms in eosinophilic esophagitis, but this setback doesn't impact its promising ongoing urticaria programs. Phase 3 trials for chronic ...

On Tuesday, Celldex Therapeutics, Inc. (NASDAQ:CLDX) released topline results from its ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the ...

Tel Aviv: Israeli scientists have discovered that blocking a specific protein may stop a painful food allergy-related disease before it starts. The finding, Tel Aviv University announced on Monday, ...